BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 36154845)

  • 1. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
    Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
    Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
    Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
    Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.
    Ingelman-Sundberg M; Pirmohamed M
    J Intern Med; 2024 May; 295(5):583-598. PubMed ID: 38343077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic profile of a central European urban random population-Czech population.
    Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
    PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.
    de Lara DV; de Melo DO; Araújo Silva LC; Gonçalves TS; Júnior Lima Santos PC
    Pharmacogenomics; 2022 May; 23(7):443-452. PubMed ID: 35380455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
    Johnson JA; Cavallari LH
    Pharmacol Rev; 2013 Jul; 65(3):987-1009. PubMed ID: 23686351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
    Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
    Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
    Matey ET; Ragan AK; Oyen LJ; Vitek CR; Aoudia SL; Ragab AK; Fee-Schroeder KC; Black JL; Moyer AM; Nicholson WT; Shrestha S; McAllister TM; Sinnwell JP; Faubion SS; Lazaridis KN
    Pharmacogenomics J; 2022 Feb; 22(1):69-74. PubMed ID: 34671112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applied pharmacogenomics in cardiovascular medicine.
    Weeke P; Roden DM
    Annu Rev Med; 2014; 65():81-94. PubMed ID: 24111889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
    Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
    J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of drugs with pharmacogenomics (PGx)-based dosing guidelines in a Danish cohort of persons with chronic kidney disease, both on dialysis and not on dialysis: Perspectives for prescribing optimization.
    Westergaard N; Baltzer Houlind M; Christrup LL; Juul-Larsen HG; Strandhave C; Olesen AE
    Basic Clin Pharmacol Toxicol; 2024 Apr; 134(4):531-542. PubMed ID: 38308569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fetal pharmacogenomics: A promising addition to complex neonatal care.
    Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
    Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
    Zhu Y; Moriarty JP; Swanson KM; Takahashi PY; Bielinski SJ; Weinshilboum R; Wang L; Borah BJ
    Genet Med; 2021 Mar; 23(3):461-470. PubMed ID: 33041335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.
    Pratt VM; Cavallari LH; Del Tredici AL; Hachad H; Ji Y; Kalman LV; Ly RC; Moyer AM; Scott SA; Whirl-Carrillo M; Weck KE
    J Mol Diagn; 2020 Jul; 22(7):847-859. PubMed ID: 32380173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
    Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
    Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
    Hirata TDC; Dagli-Hernandez C; Genvigir FDV; Lauschke VM; Zhou Y; Hirata MH; Hirata RDC
    Mol Diagn Ther; 2021 Nov; 25(6):735-755. PubMed ID: 34357562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
    Langaee T; El Rouby N; Stauffer L; Galloway C; Cavallari LH
    Genet Test Mol Biomarkers; 2019 Mar; 23(3):209-214. PubMed ID: 30758238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.